risdiplam
Generic: RISDIPLAM·Brand: EVRYSDI, Evrysdi
risdiplam: 2 clinical trials tracked.
risdiplam evidence translation
What we can confirm
2 tracked trials
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about risdiplam, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (2)
A Phase 2, Double-Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Apitegromab in Subjects <2 Years Old With Spinal Muscular Atrophy (SMA)
Primary endpoint: Evaluate the PK of apitegromab in subjects <2 years old with SMA
InterventionalRandomizedquadruple52 targetStarted 2025-09Completion 2029-0325 sites · Belgium, France, Italy, Netherlands…Scholar Rock, Inc.
A Phase II, Open-label Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
Primary endpoint: Plasma Concentrations of Risdiplam
Interventionalopen10 targetStarted 2024-04Completion 2026-1113 sites · Belgium, Canada, Germany, Italy…Hoffmann-La Roche